Reduced Vessel Density of the Choriocapillaris during Anti-Vascular Endothelial Growth Factor Therapy for Neovascular Age-Related Macular Degeneration

被引:30
|
作者
Hikichi, Taiichi [1 ]
Agarie, Mitsuko [2 ]
机构
[1] Hikichi Eye Clin, Sapporo, Hokkaido, Japan
[2] Carl Zeiss Meditec Co Ltd, Tokyo, Japan
关键词
anti-VEGF; choriocapillaris; neovascular age-related macular degeneration; optical coherence tomography angiography; vessel density; COHERENCE TOMOGRAPHY ANGIOGRAPHY; POLYPOIDAL CHOROIDAL VASCULOPATHY; VERTEPORFIN PHOTODYNAMIC THERAPY; RETINAL-PIGMENT EPITHELIUM; FOVEAL AVASCULAR ZONE; ANTI-VEGF TREATMENT; QUANTITATIVE-ANALYSIS; VASCULAR DENSITY; RANIBIZUMAB; ATROPHY;
D O I
10.1167/iovs.18-24522
中图分类号
R77 [眼科学];
学科分类号
100212 ;
摘要
PURPOSE. To investigate macular vascular alterations by using optical coherence tomography angiography (OCTA) in patients with a history of long-term anti-vascular endothelial growth factor (VEGF) therapy for neovascular age-related macular degeneration (nAMD). METHODS. Japanese patients with nAMD with a history of long-term anti-VEGF monotherapy at study entry were studied retrospectively. OCTA images were obtained, and the vessel densities (mm(-1)) of the superficial capillary plexus, deep capillary plexus (DCP), choriocapillaris (CC), and the plexus foveal avascular zone area (mm(2)) were calculated. RESULTS. One hundred twenty-four eyes (124 patients) were included. The mean +/- standard deviation follow-up period between the first and last OCTA imaging sessions was 14.5 +/- 3.1 months; the duration of the anti-VEGF monotherapy before the first OCTA imaging session was 68.0 +/- 23.6 months, with a mean of 3.6 +/- 3.0 injections during the follow-up period. The vessel densities of the DCP and CC significantly decreased (P = 0.001 and P = 0.009, respectively) from 10.62 +/- 2.72 mm(-1) and 11.84 +/- 1.79 mm(-1) to 9.44 +/- 2.88 mm(-1) and 11.18 +/- 2.12 mm(-1). Such findings were not observed in 63 control eyes. CONCLUSIONS. The DCP and CC deteriorate during treatment. This information may guide future treatment strategies for nAMD, such as the need to protect the capillaries to maintain visual acuity after long-term treatment. Prospective, controlled trials are required to confirm our findings.
引用
收藏
页码:1088 / 1095
页数:8
相关论文
共 50 条
  • [31] Caregiver Experience Survey of Anti-Vascular Endothelial Growth Factor Treatment for Diabetic Macular Edema and Neovascular Age-Related Macular Degeneration
    Viola, Francesco
    Chi, Gloria C.
    Holekamp, Nancy M.
    Giocanti-Auregan, Audrey
    Garcia-Layana, Alfredo
    Peto, Tunde
    Kertes, Peter J.
    Mirt, Mirela
    Kotecha, Aachal
    Lambert, Jeremy
    Lewis, Hannah B.
    Gentile, Brittany
    OPHTHALMIC RESEARCH, 2024, 67 (01) : 516 - 527
  • [32] Outcome of anti-vascular endothelial growth factor therapy for neovascular age-related macular degeneration in real-life setting
    Kataja, Maria
    Hujanen, Pekko
    Huhtala, Heini
    Kaarniranta, Kai
    Tuulonen, Anja
    Uusitalo-Jarvinen, Hannele
    BRITISH JOURNAL OF OPHTHALMOLOGY, 2018, 102 (07) : 959 - 965
  • [33] Patient Preferences Associated with Anti-Vascular Endothelial Growth Factor Therapies for Neovascular Age-Related Macular Degeneration and Diabetic Macular Edema
    Bhagat, Davis
    Kirby, Breanne
    Bhatt, Harit
    Jager, Rama
    George, Meena
    Sheth, Veeral
    CLINICAL OPHTHALMOLOGY, 2020, 14 : 2975 - 2982
  • [34] Anti-vascular endothelial growth factor for neovascular age-related macular degeneration in 2022: Same, same but different
    Fung, Adrian T.
    CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY, 2022, 50 (03) : 270 - 273
  • [35] Effects of delay in anti-vascular endothelial growth factor intravitreal injections for neovascular age-related macular degeneration
    Joel Hanhart
    Rony Wiener
    Hashem Totah
    Evgeny Gelman
    Yishay Weill
    Adi Abulafia
    David Zadok
    Graefe's Archive for Clinical and Experimental Ophthalmology, 2022, 260 : 1907 - 1914
  • [36] Anti vascular endothelial growth factor sequential therapy for neovascular age-related macular degeneration: is this the new deal?
    Neri, Piergiorgio
    Mariotti, Cesare
    Arapi, Ilir
    Bambini, Elisa
    Giovannini, Alfonso
    CURRENT MEDICAL RESEARCH AND OPINION, 2012, 28 (03) : 395 - 400
  • [37] Retinal Pigment Epithelium Tears after Anti-Vascular Endothelial Growth Factor Therapy for Neovascular Age-Related Macular Degeneration
    Ahn, Jayoung
    Hwang, Daniel Duck-Jin
    Sohn, Joonhong
    Son, Gisung
    OPHTHALMOLOGICA, 2022, 245 (01) : 1 - 9
  • [38] ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPY FOR NEOVASCULAR AGE-RELATED MACULAR DEGENERATION Outcomes in Eyes With Poor Initial Vision
    Toth, Levente A.
    Stevenson, Michael
    Chakravarthy, Usha
    RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES, 2015, 35 (10): : 1957 - 1963
  • [39] Outcomes of cataract surgery in patients with neovascular age-related macular degeneration in the era of anti-vascular endothelial growth factor therapy
    Tabandeh, Homayoun
    Chaudhry, Nauman A.
    Boyer, David S.
    Kon-Jara, Veronica A.
    Flynn, Harry W., Jr.
    JOURNAL OF CATARACT AND REFRACTIVE SURGERY, 2012, 38 (04) : 677 - 682
  • [40] Insights From Survival Analyses During 12 Years of Anti-Vascular Endothelial Growth Factor Therapy for Neovascular Age-Related Macular Degeneration
    Fu, Dun Jack
    Keenan, Tiarnan D.
    Faes, Livia
    Lim, Ernest
    Wagner, Siegfried K.
    Moraes, Gabriella
    Huemer, Josef
    Kern, Christoph
    Patel, Praveen J.
    Balaskas, Konstantinos
    Sim, Dawn A.
    Bunce, Catey
    Stratton, Irene
    Keane, Pearse A.
    JAMA OPHTHALMOLOGY, 2021, 139 (01) : 57 - 67